The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors ; volume:9 ; number:1 ; day:13 ; month:3 ; year:2019 ; pages:1-9 ; date:12.2019
Scientific reports ; 9, Heft 1 (13.3.2019), 1-9, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Coperchini, Francesca
Croce, Laura
Denegri, Marco
Awwad, Oriana
Ngnitejeu, Samuel Tata
Muzza, Marina
Capelli, Valentina
Latrofa, Francesco
Persani, Luca
Chiovato, Luca
Rotondi, Mario
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-40818-w
- URN
-
urn:nbn:de:101:1-2019033116311523353678
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Coperchini, Francesca
- Croce, Laura
- Denegri, Marco
- Awwad, Oriana
- Ngnitejeu, Samuel Tata
- Muzza, Marina
- Capelli, Valentina
- Latrofa, Francesco
- Persani, Luca
- Chiovato, Luca
- Rotondi, Mario
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing